Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Redpin Therapeutics

Request full access

We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system

New York City, United StatesFounded 2017Biotech & Life Sciences

About Redpin Therapeutics

Redpin Therapeutics operates at the intersection of biotechnology and neuroscience, focusing on the development of chemogenetic therapies. The company leverages pioneering research to create a platform that uses anti-smoking drugs to control neurons. This innovative approach has potential applications in both research and clinical settings. Redpin Therapeutics primarily serves pharmaceutical companies, research institutions, and healthcare providers. The market it operates in is the rapidly growing field of gene therapy and neurotechnology. The business model revolves around licensing its technology, partnering with pharmaceutical companies for drug development, and providing specialized research services. Revenue is generated through licensing fees, research grants, and collaborative agreements.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2017
Headquarters
New York City, United States
Employees
10
Open positions
None listed
Dealroom signal
56.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Nov 2022 $0 — Kriya Therapeutics ↗
SERIES AEquity / VC Jan 2021 $0 — Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Redpin Therapeutics website traffic

Latest recorded traffic for Redpin Therapeutics is 250 monthly website visits, down 28.6% over the last three months. Redpin Therapeutics's team grew 0% over the past year.

Latest monthly visits250 3-month web change-28.6% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
ZegenexNovel approaches to heal diabetic foot and other non healing wounds Pittsburgh, United States Operational 2 $215K $860K
Tianjin Hechuang BiotechnologyFocused on cell technology for pharmaceutical and health industries China Operational
Edulis TheraputicsA new therapy for Crohn's disease patients through a bioresorbable drug-delivery patch to reduce inflammation in the gut Pittsburgh, United States Operational
RogCon BiosciencesFocused on drug research, discovery and development for select ion channelopathies, with a primary focus on SCN2A Miami Beach, United States Operational
GutCrineDevelops microbiome-derived peptide therapeutics to prevent and treat cardio-metabolic and age-related disorders Rudegård, Denmark Operational
Violet TherapeuticsViolet Therapeutics is a pre-clinical stage company leveraging a first-in-class platforms to identify, map and mine the cellular connectome at scale Cambridge, United States Operational
ImmobazymeImmobazyme is a South African biotechnology spin-out company of Stellenbosch University that utilizes precision fermentation to produce high-value active protein ingredients. Stellenbosch Local Municipality, South Africa Operational
Proteo BridgeIs scheduled to give a presentation at an event called the aist startup pitch Tokyo, Japan Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Redpin Therapeutics in the New York City ecosystem

Live from Dealroom

The Redpin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • 4BIO Capital
  • Takeda Ventures
  • Arkin Capital
  • New York Ventures

Other known investors4 additional known investors

  • Kriya Therapeutics
  • Rockefeller University
  • A-Squared Ventures
  • Takeda
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Redpin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Redpin Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.